Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer

Christopher Souder, Kim Leitzel, Suhail M. Ali, Laurence Demers, Dean B. Evans, Hilary A. Chaudri-Ross, Wolfgang Hackl, Peter Hamer, Walter Carney, Allan Lipton

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

BACKGROUND. Epidermal growth factor receptor (EGFR, HER-1, and erbB1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme-linked immunoadsorbent assay in a Phase III first-line trial of letrozole and tamoxifen and were correlated with patient outcomes. RESULTS. Serum EGFR levels in a control group of 117 healthy, postmenopausal women measured 64.1 ± 13.3 ng/mL (mean ± standard deviation). Using a cutoff EGFR level of 44.1 ng/mL from the control group (5% nonparametric method), 53 of 535 patients (10%) had decreased serum levels of EGFR. Patients with decreased serum EGFR had no significant difference in objective response rate (ORR), clinical benefit rate (CBR), time to progression (TTP), or time to treatment failure (TTF); however, they did have significantly reduced survival compared with patients who had normal serum EGFR levels (median survival, 23.3 months vs. 30.9 months; P = .007). A combined analysis of pretreatment serum EGFR and HER-2 yielded no additional predictive information for ORR, CBR, TTP, or TTF compared to serum HER-2 alone. However, in the current analysis, a subgroup of patients who had decreased serum EGFR and normal serum HER-2 was identified (n = 39 of 535 patients; 7.3%) that had significantly reduced survival compared with patients who had normal serum levels of both EGFR and HER-2 (median survival, 23.5 months vs. 37.1 months; P =.005). In multivariate analysis, a decreased serum EGFR level remained a significant independent prognostic factor for decreased survival (hazards ratio, 1.58; P = .007). CONCLUSIONS. In patients who had metastatic breast cancer, decreased serum EGFR/normal serum HER-2 predicted shorter survival compared with patients who had normal levels of serum EGFR/HER-2. This patient subgroup deserves further study to assess their response to and selection for anti-EGFR-directed therapies.

Original languageEnglish (US)
Pages (from-to)2337-2345
Number of pages9
JournalCancer
Volume107
Issue number10
DOIs
StatePublished - Nov 15 2006

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer'. Together they form a unique fingerprint.

Cite this